ProSavin

#	Item
1	Page 1 of 2 Oxford BioMedica Interim Management Statement Oxford, UK – 13 May 2014: Oxford BioMedica plc (LSE: OXB), (“the Company”) the leading gene based biopharmaceutical company, today publishes its interim ma Add to Reading List Source URL: www.oxfordbiomedica.co.uk Language: English - Date: 2014-05-13 02:05:31 Pharmacology ProSavin Sanofi Pharmaceutical industry Cell therapy Biology Oxford BioMedica Pharmaceutical sciences
2	Page 1 of 2 Oxford BioMedica receives Technology Strategy Board grant for OXB-102 -- £2.2M award will be used to fund a Phase I/II clinical trial of OXB102, an enhanced version of ProSavin®; a gene therapy for the tre Add to Reading List Source URL: www.oxfordbiomedica.co.uk Language: English - Date: 2014-04-30 09:18:04 ProSavin Innovation Biotechnology Gene therapy Technology Strategy Board Biology Medicine Oxford BioMedica